OBJECTIVE: Recently, the role of hepcidin as a cardiovascular marker in the chronic kidney disease (CKD) population has gained interest. The aim of this study was to investigate the relationship between serum hepcidin-25, inflammation, iron parameters, and carotid intima-media thickness (CIMT) in peritoneal dialysis (PD) patients. METHODS: A total of 58 patients (30 male, 51.3%; mean age: 46.8±13.6 years; mean dialysis duration: 69.2±39.1 months) were included in this cross-sectional study. Clinical and routine laboratory data were recorded and the CIMT and hepcidin values were determined. The study population was divided into 2 groups according to the median hepcidin value of 60 ng/mL. Correlation analysis and logistic regression analysis were performed to determine the relationship between the hepcidin level and other parameters. RESULTS: Age (p=0.003), systolic blood pressure (p=0.039), body mass index (p=0.031), glucose (p=0.028) level, C-reactive protein (CRP) level (p<0.001), and CIMT (p=0.011) were found to be statistically significantly higher in the high hepcidin group. In correlation analysis, hepcidin was positively correlated with age (p<0.001), dialysis duration (p=0.041), glucose (p=0.015), ferritin (p=0.005), CRP (p<0.001), and CIMT (p=0.035). In multivariate linear regression analysis, age (p<0.001) and CRP (p=0.005) were found to be related to CIMT. CONCLUSION: Hepcidin-25 was strongly associated with both age and CRP in patients undergoing PD treatment. The results suggest that hepcidin may be involved in the pathophysiology of atherosclerosis. Prospective studies should be carried out in this patient population to determine whether hepcidin has an effect on atherosclerosis.
OBJECTIVE: Recently, the role of hepcidin as a cardiovascular marker in the chronic kidney disease (CKD) population has gained interest. The aim of this study was to investigate the relationship between serum hepcidin-25, inflammation, iron parameters, and carotid intima-media thickness (CIMT) in peritoneal dialysis (PD) patients. METHODS: A total of 58 patients (30 male, 51.3%; mean age: 46.8±13.6 years; mean dialysis duration: 69.2±39.1 months) were included in this cross-sectional study. Clinical and routine laboratory data were recorded and the CIMT and hepcidin values were determined. The study population was divided into 2 groups according to the median hepcidin value of 60 ng/mL. Correlation analysis and logistic regression analysis were performed to determine the relationship between the hepcidin level and other parameters. RESULTS: Age (p=0.003), systolic blood pressure (p=0.039), body mass index (p=0.031), glucose (p=0.028) level, C-reactive protein (CRP) level (p<0.001), and CIMT (p=0.011) were found to be statistically significantly higher in the high hepcidin group. In correlation analysis, hepcidin was positively correlated with age (p<0.001), dialysis duration (p=0.041), glucose (p=0.015), ferritin (p=0.005), CRP (p<0.001), and CIMT (p=0.035). In multivariate linear regression analysis, age (p<0.001) and CRP (p=0.005) were found to be related to CIMT. CONCLUSION:Hepcidin-25 was strongly associated with both age and CRP in patients undergoing PD treatment. The results suggest that hepcidin may be involved in the pathophysiology of atherosclerosis. Prospective studies should be carried out in this patient population to determine whether hepcidin has an effect on atherosclerosis.